| Intrinsic Valuation of: BIOCON | |||||||||||
| Free Cash Flow Average and Growth over past 5Y | Key Statistics | ||||||||||
| Year | FCF | FCF (FCF/Revenue) | |||||||||
| 2020 | - | - | EPS (FY) | 3 | Market Cap | ₹696B | |||||
| 2021 | - | - (-) | P/E Ratio | 151 | Total Asset | ₹588B | |||||
| 2022 | ₹-7B | - (-) | Net Income | ₹10B | Total Debt | ₹124B | |||||
| 2023 | ₹1B | 116.9% (112.4%) | EBITDA | ₹45B | Total Liab | ₹311B | |||||
| 2024 | ₹10B | 710.1% (523.9%) | Opr Margin | 10.80 | Debt/Equity | 0.45 | |||||
| 2025 | ₹17B | 68.0% (58.5%) | PreTax Margin | 4.90 | BV/Share | -33 | |||||
| 5Y Average FCF | ₹5B | 15.0% (231.6%) | |||||||||
| Overall Market Assumptions: | |||||||||||
| Assumptions: | P/E for No-Growth Company: | 7.0 | |||||||||
| Perpetual Growth Rate (g): | 2.48% | Historical US Bond Yield: | 4.40% | ||||||||
| Discount Rate (WACC): | 7.02% | Current US Bond Yield: | 3.48% | ||||||||
| Forcasting Future Free Cash Flow for next 6Y | Modified Benjamin Graham's Intrinsic Value | ||||||||||
| Year | FCF Projection (15.0%) | ||||||||||
| 2026 | ₹17B | MBG Intrinsic Value | ₹25 | ||||||||
| 2027 | ₹19B | ||||||||||
| 2028 | ₹21B | ||||||||||
| 2029 | ₹23B | ||||||||||
| 2030 | ₹24B | ||||||||||
| 2031 | ₹25B | ||||||||||
| Terminal Value | ₹553B | Net Worth/Share | ₹171 | ||||||||
| DCF Valuation | DCF Valuation "What If" Scenario Table | ||||||||||
| Enterprise Value | ₹469B | Growth Rate | |||||||||
| (+) Cash & Cash Equivalents | ₹32B | ₹233 | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | ||||
| (-) Total Debt | ₹124B | WACC | 6.5% | 216 | 241 | 271 | 310 | 362 | |||
| Equity Value | ₹377B | 7.1% | 185 | 204 | 226 | 254 | 289 | ||||
| Shares Outstanding | 1,619,331,350 | 7.8% | 160 | 175 | 192 | 212 | 238 | ||||
| 8.4% | 140 | 151 | 165 | 181 | 200 | ||||||
| DCF Intrinsic Value | ₹233 | 9.0% | 123 | 132 | 143 | 155 | 170 | ||||
| Analyzed by QuantJuice (2025) | |||||||||||